People: Achillion Pharmaceuticals Inc (ACHN.O)

ACHN.O on Nasdaq

6.91USD
23 Jul 2014
Price Change (% chg)

$0.08 (+1.17%)
Prev Close
$6.83
Open
$6.92
Day's High
$7.12
Day's Low
$6.84
Volume
2,660,312
Avg. Vol
6,397,989
52-wk High
$8.61
52-wk Low
$2.26

Search Stocks

Kishbauch, Michael 

Brief Biography

Mr. Michael D. Kishbauch is Director of Achillion Pharmaceuticals Inc. From September 1996 to July 2004, Mr. Kishbauch founded and served as President and Chief Executive Officer of OraPharma, Inc., a publicly traded, commercial-stage pharmaceutical company focused on oral health care, which was acquired by Johnson & Johnson in 2003. Prior to OraPharma, Inc., Mr. Kishbauch held senior management positions with MedImmune, Inc. Mr. Kishbauch holds a M.B.A. from the Wharton School of the University of Pennsylvania and a B.A. in biology from Wesleyan University. Mr. Kishbauch has held senior management positions in the life sciences industry for over 28 years.

Basic Compensation

Total Annual Compensation, USD Long-Term Incentive Plans, USD All Other, USD Fiscal Year Total, USD
368,635 -- 7,911 376,546

Options Compensation

  Quantity Market Value
Exercisable 3,101,000 --
Unexercisable -- --
Exercised 297,415 2,762,190.00
Name Fiscal Year Total

David Scheer

--

Milind Deshpande

4,853,430

Mary Kay Fenton

989,616

Gautam Shah

883,243

David Apelian

2,175,130

Joseph Truitt

886,617
As Of 30 Dec 2013
Search Stocks